UK clinical guideline for the prevention and treatment of osteoporosis
CL Gregson, DJ Armstrong, J Bowden, C Cooper… - Archives of …, 2022 - Springer
Abstract Summary The National Osteoporosis Guideline Group (NOGG) has revised the UK
guideline for the assessment and management of osteoporosis and the prevention of …
guideline for the assessment and management of osteoporosis and the prevention of …
Postmenopausal osteoporosis
Key Clinical Points Postmenopausal Osteoporosis Fractures and osteoporosis are common,
particularly among older women, and hip fractures can be devastating. Treatment is …
particularly among older women, and hip fractures can be devastating. Treatment is …
[HTML][HTML] The clinician's guide to prevention and treatment of osteoporosis
MS LeBoff, SL Greenspan, KL Insogna… - Osteoporosis …, 2022 - Springer
Osteoporosis is the most common metabolic bone disease in the USA and the world. It is a
subclinical condition until complicated by fracture (s). These fractures place an enormous …
subclinical condition until complicated by fracture (s). These fractures place an enormous …
Clinician's guide to prevention and treatment of osteoporosis
F Cosman, SJ de Beur, MS LeBoff, EM Lewiecki… - Osteoporosis …, 2014 - Springer
Abstract The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed
by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with …
by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with …
Romosozumab or alendronate for fracture prevention in women with osteoporosis
Background Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin,
increases bone formation, and decreases bone resorption. Methods We enrolled 4093 …
increases bone formation, and decreases bone resorption. Methods We enrolled 4093 …
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
SR Cummings, JS Martin, MR McClung… - … England Journal of …, 2009 - Mass Medical Soc
Background Denosumab is a fully human monoclonal antibody to the receptor activator of
nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the …
nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the …
Incidence and economic burden of osteoporosis‐related fractures in the United States, 2005–2025
R Burge, B Dawson‐Hughes… - Journal of bone and …, 2007 - academic.oup.com
This study predicts the burden of incident osteoporosis‐related fractures and costs in the
United States, by sex, age group, race/ethnicity, and fracture type, from 2005 to 2025. Total …
United States, by sex, age group, race/ethnicity, and fracture type, from 2005 to 2025. Total …
UK clinical guideline for the prevention and treatment of osteoporosis
Abstract Introduction In 2008, the UK National Osteoporosis Guideline Group (NOGG)
produced a guideline on the prevention and treatment of osteoporosis, with an update in …
produced a guideline on the prevention and treatment of osteoporosis, with an update in …
[HTML][HTML] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Background A single infusion of intravenous zoledronic acid decreases bone turnover and
improves bone density at 12 months in postmenopausal women with osteoporosis. We …
improves bone density at 12 months in postmenopausal women with osteoporosis. We …
Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians
A Qaseem, LA Hicks… - Annals of internal …, 2023 - acpjournals.org
An update is available for this article. Description: This guideline updates the 2017 American
College of Physicians (ACP) recommendations on pharmacologic treatment of primary …
College of Physicians (ACP) recommendations on pharmacologic treatment of primary …